Answer this question, get featured on Men's Journal

M

MDlinxWe are looking for physician perspectives on patients combining GLP-1 receptor agonists with growth hormone–related peptides or recovery stacks. We want practical insights on risks, monitoring, and patient expectations. Questions: 1. Are you seeing patients combine GLP-1 receptor agonists with growth hormone–related peptides, and what concerns do you have regarding muscle loss, metabolic effects, or long-term outcomes? 2. What baseline assessments and follow-up strategies do you recommend for patients on GLP-1 therapies to preserve lean mass and minimize complications? 3. How do you counsel patients who expect rapid or sustained results from combining pharmacologic agents without addressing nutrition and resistance training?

M

MDlinxWe are gathering input from clinicians on patients experimenting with multi-peptide stacks for recovery, fat loss, or performance. We are interested in practical perspectives on risks, monitoring, and patient counseling. Questions: What concerns do you have about patients using multi-peptide stacks, and what physiologic or pharmacologic risks do you think are most underappreciated? Do you follow a structured approach when counseling patients experimenting with multiple peptides, such as single-agent trials or lab monitoring, and what does that framework look like in your practice? Have you seen cases where peptide stacking led to unexpected adverse effects or diagnostic confusion, and what lessons should clinicians take from those experiences?

M

MDlinxWe are speaking with physicians about the surge in patient interest in peptides such as BPC-157, TB-500, and mitochondrial peptides sourced online. We are looking for brief, experience-based insights on how this is showing up in clinical practice and how you counsel patients. Short quotes are welcome. 1. What trends are you seeing in how patients are sourcing and using these peptides? 2. What risks or complications have you encountered, including contamination, dosing variability, or adverse effects? 3. How do you guide patients toward safer, evidence-based alternatives when they request these compounds?

This deadline has passed

View Similar Opportunities